Home › Funds › THIRD AVENUE MANAGEMENT LLC › CPRX

THIRD AVENUE MANAGEMENT LLC position in CPRX

CATALYST PHARMACEUTICALS INC

THIRD AVENUE MANAGEMENT LLC reported holding 210,161 shares of CPRX (CATALYST PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$6.6M, representing 1.06% of its reported portfolio and ranking #31 among its reported holdings. THIRD AVENUE MANAGEMENT LLC has disclosed CPRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

Latest position (Q2 2026)210.16K sh
Reported value held$6.61M
Portfolio Weight1.06%
First reportedQ1 2026
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How THIRD AVENUE MANAGEMENT LLC's CPRX position evolved

THIRD AVENUE MANAGEMENT LLC first disclosed a stake in CPRX in Q1 2026 at 210,161 shares (US$5.2M). The position peaked in Q2 2026 at 210,161 shares, worth US$6.6M. Across 2 filings, THIRD AVENUE MANAGEMENT LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 210,161 shares valued at US$6.6M.

Quarter by quarter

QuarterSharesValueChange
Q1 2026 210.16K $5.20M New
Q2 2026 210.16K $6.61M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CPRX and 13F data

CPRX (CATALYST PHARMACEUTICALS INC) is a company whose sector is not yet classified in our data. 43 other funds we track also report a position in CPRX — the largest reported positions include GLAZER CAPITAL, LLC (US$113.2M), HBK INVESTMENTS L P (US$88.6M), NEXPOINT ASSET MANAGEMENT, L.P. (US$50.4M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CPRX

All CPRX fund holders →

FAQ

How long has THIRD AVENUE MANAGEMENT LLC held CPRX?

THIRD AVENUE MANAGEMENT LLC has disclosed CPRX holdings in 2 of the last 2 reported quarters, going back to Q1 2026.

What is THIRD AVENUE MANAGEMENT LLC's current position in CPRX?

As of Q2 2026, THIRD AVENUE MANAGEMENT LLC holds 210.16K shares of CPRX (CATALYST PHARMACEUTICALS INC), valued at $6.61M, representing 1.06% of its reported portfolio and ranking #31.

Has THIRD AVENUE MANAGEMENT LLC been buying or selling CPRX?

In the latest 13F filing (Q2 2026), THIRD AVENUE MANAGEMENT LLC held unchanged its position in CPRX. The position peaked in Q2 2026 at 210.16K shares.

Which other funds hold CPRX?

Other major institutional holders of CPRX include GLAZER CAPITAL, LLC, HBK INVESTMENTS L P, NEXPOINT ASSET MANAGEMENT, L.P., among 43 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.